Helou, Doumet Georges http://orcid.org/0000-0002-5835-9214
Shafiei-Jahani, Pedram
Lo, Richard
Howard, Emily
Hurrell, Benjamin P.
Galle-Treger, Lauriane
Painter, Jacob D. http://orcid.org/0000-0003-0273-8597
Lewis, Gavin
Soroosh, Pejman
Sharpe, Arlene H. http://orcid.org/0000-0002-9736-2109
Akbari, Omid http://orcid.org/0000-0002-4359-9725
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Center for Research Resources (R01 ES025786, R01 ES021801, R01 HL144790, R21 AI109059)
Article History
Received: 21 February 2020
Accepted: 15 July 2020
First Online: 10 August 2020
Competing interests
: A.H.S. declares that they have patents/pending royalties on the PD-1 pathway from Roche and Novartis. G.L. and P.S. declare that they are employees of Janssen R&D. O.A. declares that they receive grant support from the NIH and Janssen Pharmaceuticals. The other authors declare no competing interests.